The Role of microRNAs in Gliomas and Their Potential Applications for Diagnosis and Treatment

Lavon, Iris

doi:10.5772/25003

Cited by 1 publication

(2 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…miRNAs serve crucial functions in tumorigenesis, angiogenesis, invasion and apoptosis for various types of tumor (10)(11)(12). Previous studies have identified the dysregulation of specific miRNAs in malignant gliomas, and numerous miRNAs are known to be involved in the pathogenesis of gliomas, with a number useful for the diagnosis and treatment of gliomas (13)(14)(15)(16)(17)(18). miR-21, one of the most common miRNAs identified by previous studies of gliomas, has been demonstrated to function as an antiapoptotic factor, which targets a network of p53, transforming growth factor-β and mitochondrial apoptosis tumor suppressor genes in glioblastoma cells (38,39).…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies have indicated that miRNAs are involved in a range of physiological processes in tumor cells, including cell differentiation, apoptosis and metabolism, which play a crucial role in tumor development and progression (10)(11)(12). Furthermore, numerous studies have indicated that miRNAs are involved in the pathogenesis of gliomas, and may subsequently be useful in the diagnosis and treatment of (13)(14)(15)(16)(17)(18). However, to the best of our knowledge, the role of miR-200b in the pathogenesis of gliomas remains unknown.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Associations between SOX2 and miR-200b expression with the clinicopathological characteristics and prognosis of patients with glioma

Wang

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. The aim of the present study was to investigate the associations between microRNA (miR)-200b and sex determining region Y-box 2 (SOX2) expression with gender, age, clinical staging and pathological staging in 123 patients with glioma. The results revealed higher miR-200b expression levels in the glioma tissue than in the normal brain tissues, and a reduction in miR-200b expression with increasing pathological grading of the gliomas. Immunohistochemistry revealed a 53.7% gross expression rate of SOX2 in the glioma tissues. SOX2 and miR-200b expression levels were significantly correlated with the histological grading of the gliomas (P<0.05); however, no associations were observed with patient gender, age, pathological classification or clinical staging of the glioma (P>0.05). In patients with grade I and II gliomas, no correlation was detected between miR-200b and SOX2, while a significant correlation was observed in grade III and IV gliomas. A median 52-month follow-up revealed 1-, 3-and 5-year gross survival rates of 82.1, 50.0 and 30.7%, respectively, in the 123 patients with a glioma. Univariate analysis revealed no association between survival rate and patient age, gender, Karnofsky Performance Scale score, histological grading or clinical staging (P>0.05). However, miR-200b and SOX2 were independent prognostic factors for glioma (P<0.05). Patients with positive SOX2 expression exhibited a significantly reduced 5-year survival rate, compared with those with negative SOX2 expression (P<0.001). Furthermore, a significantly higher 5-year survival rate was observed in patients with high miR-200b expression than those with low miR-200b expression (P<0.001). The results indicated that SOX2 and miR-200b expression levels are associated with the histological grading of gliomas, but do not correlate with patient gender or age, or the pathological classification or clinical staging of the gliomas. Thus, miR-200b and SOX2 offer useful independent prognostic factors for glioma.

show abstract